SNCA and Parkinson disease: To further characterize and prove the ability of the post immune antisera elicited from the vaccine candidates to recognize the structure of alpha‐synuclein fibrils instead of linear peptides/epitopes of alpha‐synuclein in their native form, we tested the antisera with human brain lysates from patients who died with DLB, MSA or PD, and non‐neurologic controls (Table 1), as well as with a set of linear peptides that comprised the entire sequence of alpha‐synuclein (Figure 6).